Cannabidiol reduced the severity of gastrointestinal symptoms of opioid withdrawal in male and female mice in a new study that researchers believe has strong implications for helping humans withdrawing from opioids.
As noted by the study’s researchers, although the negative symptoms of opioid withdrawal impacts potentially millions of people, there are “currently limited treatment options available for opioid withdrawal and cannabidiol (CBD) has been identified as a potential novel therapeutic.”
With that in mind, this study “explored the efficacy and dose dependency of CBD for reducing the severity of naloxone-precipitated and spontaneous oxycodone withdrawal (PW and SW, respectively) in male and female mice.” The study was published in the December, 2022 issue of the peer-reviewed journal Cannabis and Cannabinoids Research, and was epublished ahead of print on the website for the National Library of Medicine.
Continue reading